S086 Tablets for Chronic Heart Failure With Reduced Ejection Fraction

Inclusion criteria

• Patients with chronic heart failure (NYHA grade ⅱ-ⅳ) with reduced ejection fraction (LVEF≤40%) and elevated BNP were diagnosed 1a.
• Patients received a stable dose of the underlying treatment for heart failure, defined as no change in dose for at least 4 weeks before screening 1b.
• Volunteer to participate in the trial and sign an informed consent form 1c.

Exclusion criteria

• Previous continuous administration of sacubitril valsartan sodium 150mg bid or more for more than 3 months 1a.
• Use of other study drugs or use of any study medical device within 1 day of the visit or within 30 days prior to the visit or within 5 half-lives of the drug, whichever is longer 1b.
• Known or suspected allergy to S086, sacubitril valsartan sodium, ARB, ACEI, or enkephin inhibitor (NEPI), and known or suspected contraindications to sacubitril valsartan sodium 1c.
• A previous history of intolerance to the recommended target dose of ACEI or ARB 1d.
• He had a history of angioedema 1e.
• Acute coronary syndrome occurred within 6 weeks before visit 1 1f.